The Union health ministry on Friday said license has been given to five more manufacturers for production of Amphotericin-B, used in the treatment of black fungus, and they will start producing......
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and......
10 non-bank and non-finance stocks from the BSE500 Index universe that offer an optimal blend of low valuation, reasonably robust revenue and earnings growth in recent quarters, a strong balance......
An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India’s pharmaceutical companies during the first quarter of this financial......
Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication in the US market, are likely to benefit. The cold wave in the US may bring big business for......
Analysts attribute this outperformance to the government's proactive economic reform measures Illustration: Uttam Ghosh/Rediff.com Mid-and small-cap indices have outperformed large-caps in the......